ATE227133T1 - Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber - Google Patents

Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber

Info

Publication number
ATE227133T1
ATE227133T1 AT95910629T AT95910629T ATE227133T1 AT E227133 T1 ATE227133 T1 AT E227133T1 AT 95910629 T AT95910629 T AT 95910629T AT 95910629 T AT95910629 T AT 95910629T AT E227133 T1 ATE227133 T1 AT E227133T1
Authority
AT
Austria
Prior art keywords
alpha
ifn
pct
treating viral
interferon
Prior art date
Application number
AT95910629T
Other languages
English (en)
Inventor
Graham Russell Foster
Howard Christopher Thomas
Original Assignee
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404379A external-priority patent/GB9404379D0/en
Priority claimed from GB9420340A external-priority patent/GB9420340D0/en
Application filed by Imperial College filed Critical Imperial College
Application granted granted Critical
Publication of ATE227133T1 publication Critical patent/ATE227133T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT95910629T 1994-03-07 1995-03-07 Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber ATE227133T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9404379A GB9404379D0 (en) 1994-03-07 1994-03-07 Therapeutic improvement
GB9420340A GB9420340D0 (en) 1994-10-10 1994-10-10 Therapeutic improvement
PCT/GB1995/000488 WO1995024212A1 (en) 1994-03-07 1995-03-07 The use of interferon subtypes in the preparation of medicaments to treat viral infections

Publications (1)

Publication Number Publication Date
ATE227133T1 true ATE227133T1 (de) 2002-11-15

Family

ID=26304449

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95910629T ATE227133T1 (de) 1994-03-07 1995-03-07 Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber

Country Status (10)

Country Link
US (1) US6007805A (de)
EP (1) EP0741577B1 (de)
JP (1) JP4001379B2 (de)
AT (1) ATE227133T1 (de)
AU (1) AU1854695A (de)
DE (1) DE69528751T2 (de)
DK (1) DK0741577T3 (de)
ES (1) ES2186714T3 (de)
PT (1) PT741577E (de)
WO (1) WO1995024212A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
GB9702021D0 (en) * 1997-01-31 1997-03-19 Imperial College Medicaments
US6436391B1 (en) * 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
IT1295657B1 (it) * 1997-11-04 1999-05-24 Alfa Wassermann Spa Oligopeptidi antiparalleli e oligopeptidi idrofobicamente complementari, matrici che li contengono e loro uso nella
ES2138565B1 (es) * 1998-05-13 2000-08-16 Inst Cientifico Tecnol Navarra Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
GB9818445D0 (en) * 1998-08-24 1998-10-21 Imp College Innovations Ltd Medicaments
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2005046715A1 (ja) * 2003-11-12 2005-05-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 生理活性複合体
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CA2607651A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
EP2020990B1 (de) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
KR20110005806A (ko) 2008-03-21 2011-01-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인간 인터페론 α 서브타입 α8 및 그 변이 단백질을 특이적으로 인식하는 단일클론 항체
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
GB201215873D0 (en) * 2012-09-05 2012-10-24 Alfacyte Ltd Compositions and methods relating to the treatment of allergy and allergic diseases
GB201404403D0 (en) * 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
HUE065662T2 (hu) 2015-09-15 2024-06-28 Ilc Therapeutics Ltd Készítmények és eljárások betegségek kezelésére
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH651308A5 (de) * 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
GB8303165D0 (en) * 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
JPH02197539A (ja) * 1989-01-26 1990-08-06 Tanaka Kikinzoku Kogyo Kk 装飾品用Ｃｏ含有貴金属材料
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5503828A (en) * 1992-02-10 1996-04-02 Interferon Sciences, Inc. Alpha interferon composition and method for its production from human peripheral blood leukocytes

Also Published As

Publication number Publication date
EP0741577B1 (de) 2002-11-06
PT741577E (pt) 2003-03-31
DE69528751T2 (de) 2003-07-10
JPH09509955A (ja) 1997-10-07
WO1995024212A1 (en) 1995-09-14
EP0741577A1 (de) 1996-11-13
JP4001379B2 (ja) 2007-10-31
ES2186714T3 (es) 2003-05-16
DE69528751D1 (de) 2002-12-12
AU1854695A (en) 1995-09-25
US6007805A (en) 1999-12-28
DK0741577T3 (da) 2003-02-17

Similar Documents

Publication Publication Date Title
DE69528751D1 (de) Verwendung von Interferon-alpha 8 subtype zur Herstellung von Medikamenten zur Behandlung von Viralinfektionen der Leber
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE164067T1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69324671D1 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
ES2125976T3 (es) Otros derivados de indol con accion antiviral.
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
DE69310528D1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
DE69531150D1 (de) Verwendung von biopolymeren zur behandlung der muskeln
DE10299005I1 (de) Verwendung von 1-Beta-D-ribofuranosyl-1,2,4-triazol-3-carboxamid (Ribavirin) zur Herstellung eines Medikaments fuer die Behandlung von Arboviren
ATE190492T1 (de) Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
EP0757697A4 (de) Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE174507T1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0741577

Country of ref document: EP

REN Ceased due to non-payment of the annual fee